Feature | December 28, 2012

American College of Cardiology Names Top Cardiovascular Stories of 2012

Top Cardiovascular Stories 2012 Software CT angiography Heart Valve Repair

December 28, 2012 — The past year in cardiology has continued to see progress and innovation in medicine. As the year comes to an end, the American College of Cardiology (ACC) identified some of the top cardiovascular stories of 2012.

Electronic applications moved into the doctor’s office. iPhone apps were introduced to generate electrocardiograms (ECGs), help diagnose atrial fibrillation or help patients quit smoking, while the ACC’s CardioSmart Explorer app was introduced to provide animated 3-D heart images to help cardiologists explain conditions to their patients.

The Choosing Wisely campaign got national attention. Medical societies, including the ACC, identified over-performed procedures that physicians and patients should discuss together. The campaign was meant to help open the discussion between patients and providers about the costs, risks and benefits of certain procedures.

The Affordable Care Act upheld. In June, the U.S. Supreme Court upheld the majority of the Affordable Care Act, with the court ruling the individual mandate was constitutional as a tax.

Bariatric surgery identified as tool for controlling diabetes in some. A new study, presented at ACC.12 in Chicago, found bariatric surgery with medical therapy was better than intensive medical therapy alone for controlling blood sugar in obese patients with type 2 diabetes.

The U.S Food and Drug Administration (FDA) expanded approved uses for transcatheter aortic valve replacement (TAVR). The FDA approved TAVR for high-risk patients. Previously, the FDA had approved the treatment for only inoperable patients.

Warfarin alternative approved. FDA approval was also given to rivaroxaban, a warfarin alternative, to treat pulmonary embolism and deep vein thrombosis.

Surgery identified as better than stents for some patients. Coronary artery bypass grafting (CABG) was shown in a study to be better than percutaneous coronary intervention (PCI) for treatment of patients with diabetes and multi-vessel coronary artery disease.

New cholesterol-lowering drug showed potential. PCSK9 inhibitors demonstrated success in significantly lowering LDL cholesterol. This development opens the door to promising new techniques and medicines for lowering cholesterol.

• Generic drugs impacted consumers. Generic forms of cholesterol-lowering statin Lipitor were marketed in 2012, and the patent for Plavix expired, leading to the FDA approval of generic alternatives.

For more information: www.cardiosource.org/ACC

Related Content

Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
CardiAQ, Neovasc, lawsuit, TMVR
News | Business| May 24, 2016
Edwards Lifesciences Corp. announced that a federal jury in Boston returned a verdict in favor of CardiAQ in a lawsuit...
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies| May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There are many opinions on the duration of dual antiplatelet therapy (DAPT), highlighted at the 2016 American College
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
Overlay Init